ME Therapeutics Holdings Inc. (CNSX: METX)
Health Care · Biotechnology · CA
CA$—
— today · — 1Y
ME Therapeutics Holdings Inc. (CNSX: METX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $53.91M.
trading between 0.79 and 8.00.
Tweenvest scores ME Therapeutics Holdings Inc. across four factors: quality 26/100. Its strongest factor is quality.
METX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $53.91M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.05
- Dividend yield
- —
- Beta (5Y)
- 0.01
- 52-week high
- CA$8.00
- 52-week low
- CA$0.79
- Avg volume (3M)
- —
- Shares outstanding
- 30.39M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.34 | +0.69% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.65 | -0.04% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.57 | +1.25% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.20 | +1.02% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.33 | +0.58% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.45 | +14.08% |
Figures last refreshed Aug 18, 2026.